Morphosys said it would concentrate its research activities on its most advanced programs for its four top drugs. The four begin with Monjuvi® (tafasitamab-cxix), marketed as a therapy for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with lenalidomide; and Pelabresib (CPI-0610), being studied as a first-line treatment for myelofibrosis. MorphoSys has also committed to advancing CPI-0209, developed to treat advanced solid tumors and hematologic malignancies; and felzartamab, developed to treat Immunoglobulin A nephropathy and anti-PLA2R-positive membranous nephropathy . . .